COLLINS HELEN LOUISE (CHIEF MEDICAL OFFICER) sold 16.7% of their position (5K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $251.8K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 9/21/2026ACC: 0001701247-26-000013
Officer· CHIEF MEDICAL OFFICER
Since Feb 2026
-5K
Net shares
Net seller
$251.8K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
5K acquired · 10K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+5K
Price / share
$2.48
Trade value
$12.40K
% of position
20.0%
9/17/2026
25K→30K
Common Stock
Direct
Shares
−2.92K
Price / share
$50.03
Trade value
$145.89K
% of position
9.7%
9/17/2026
30K→27.08K
Common Stock
Direct
Shares
−1.84K
Price / share
$50.71
Trade value
$93.51K
% of position
6.8%
9/17/2026
27.08K→25.24K
Common Stock
Direct
Shares
−240.00
Price / share
$51.48
Trade value
$12.36K
% of position
1.0%
9/17/2026
25.24K→25K
Total
Net shares
+0.00
Net value
-$239.35K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/17/2026 | M · Option Exercise | +5K | $2.48 | $12.40K | 20.0% | 25K | 30K |
| Common Stock Direct | 9/17/2026 | S · Sale | −2.92K | $50.03 | $145.89K | 9.7% | 30K | 27.08K |
| Common Stock Direct | 9/17/2026 | S · Sale | −1.84K | $50.71 | $93.51K | 6.8% | 27.08K | 25.24K |
| Common Stock Direct | 9/17/2026 | S · Sale | −240.00 | $51.48 | $12.36K | 1.0% | 25.24K | 25K |
| Total | +0.00 | -$239.35K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
5K shares
Shares
−5K
Strike price
2.48
Held after
106.27K
Exercisable
—
9/17/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock5K shares | 9/17/2026 | M · Option Exercise | −5K | 2.48 | — | 106.27K |